ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock Holdings Boosted by Thompson Siegel & Walmsley LLC

Thompson Siegel & Walmsley LLC increased its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 23.3% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 283,860 shares of the specialty pharmaceutical company's stock after buying an additional 53,701 shares during the quarter. Thompson Siegel & Walmsley LLC owned about 1.35% of ANI Pharmaceuticals worth $15,692,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in ANIP. Pacer Advisors Inc. grew its stake in ANI Pharmaceuticals by 23,259.8% during the 3rd quarter. Pacer Advisors Inc. now owns 568,343 shares of the specialty pharmaceutical company's stock worth $33,907,000 after buying an additional 565,910 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of ANI Pharmaceuticals by 159.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company's stock valued at $33,101,000 after purchasing an additional 340,854 shares during the last quarter. abrdn plc purchased a new position in shares of ANI Pharmaceuticals in the 4th quarter valued at approximately $13,155,000. Bank of Montreal Can purchased a new position in shares of ANI Pharmaceuticals in the 3rd quarter valued at approximately $13,043,000. Finally, Mizuho Markets Americas LLC purchased a new position in shares of ANI Pharmaceuticals in the 3rd quarter valued at approximately $11,670,000. Hedge funds and other institutional investors own 76.05% of the company's stock.

Insider Buying and Selling at ANI Pharmaceuticals

In other news, CFO Stephen P. Carey sold 7,500 shares of the company's stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total value of $418,425.00. Following the completion of the sale, the chief financial officer now owns 154,468 shares of the company's stock, valued at $8,617,769.72. This represents a 4.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Meredith Cook sold 400 shares of the company's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $63.33, for a total value of $25,332.00. Following the completion of the sale, the vice president now directly owns 80,545 shares of the company's stock, valued at $5,100,914.85. The trade was a 0.49 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 10,700 shares of company stock valued at $610,201. Company insiders own 12.70% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Jefferies Financial Group assumed coverage on ANI Pharmaceuticals in a research note on Friday. They issued a "buy" rating and a $80.00 target price on the stock. Leerink Partners assumed coverage on ANI Pharmaceuticals in a research note on Wednesday, December 11th. They issued an "outperform" rating and a $80.00 target price on the stock. Guggenheim lifted their target price on ANI Pharmaceuticals from $84.00 to $86.00 and gave the company a "buy" rating in a research note on Wednesday, March 5th. StockNews.com upgraded ANI Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Friday. Finally, HC Wainwright restated a "buy" rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research note on Monday. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, ANI Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $79.75.

ANI Pharmaceuticals Trading Up 3.0 %

ANIP stock traded up $1.86 during trading on Monday, reaching $64.35. 334,305 shares of the stock traded hands, compared to its average volume of 238,236. The business's 50 day moving average price is $58.40 and its 200-day moving average price is $58.06. ANI Pharmaceuticals, Inc. has a 52-week low of $52.50 and a 52-week high of $70.81. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. The firm has a market capitalization of $1.40 billion, a PE ratio of -117.00 and a beta of 0.63.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.